Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Current Assets: 2019-2025

Historic Current Assets for IDEAYA Biosciences (IDYA) over the last 7 years, with Sep 2025 value amounting to $802.7 million.

  • IDEAYA Biosciences' Current Assets fell 13.90% to $802.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $802.7 million, marking a year-over-year decrease of 13.90%. This contributed to the annual value of $689.7 million for FY2024, which is 29.49% up from last year.
  • According to the latest figures from Q3 2025, IDEAYA Biosciences' Current Assets is $802.7 million, which was up 17.07% from $685.6 million recorded in Q2 2025.
  • IDEAYA Biosciences' Current Assets' 5-year high stood at $932.2 million during Q3 2024, with a 5-year trough of $251.0 million in Q4 2021.
  • Over the past 3 years, IDEAYA Biosciences' median Current Assets value was $689.7 million (recorded in 2024), while the average stood at $645.6 million.
  • Its Current Assets has fluctuated over the past 5 years, first skyrocketed by 244.45% in 2021, then fell by 16.91% in 2022.
  • IDEAYA Biosciences' Current Assets (Quarterly) stood at $251.0 million in 2021, then soared by 47.59% to $370.5 million in 2022, then skyrocketed by 43.78% to $532.6 million in 2023, then climbed by 29.49% to $689.7 million in 2024, then declined by 13.90% to $802.7 million in 2025.
  • Its Current Assets was $802.7 million in Q3 2025, compared to $685.6 million in Q2 2025 and $707.9 million in Q1 2025.